{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"22.4","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"The time to the best response of CR + CRh is defined as the time from the first date of study drug to the best response of CR or CRh.\n\nCR: ANC ≥ 10\\^3 /µL, platelet counts ≥ 10\\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \\< 5% blasts.\n\nCRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria:\n\n* Bone marrow with \\< 5% blasts and\n* Peripheral blood neutrophil count of \\> 0.5 × 10\\^3 /µL and\n* Peripheral blood platelet count of \\> 0.5 × 10\\^5 /µL and\n* A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection.","dispersionType":"Full Range","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.\n\nParticipants could continue receiving treatment until disease progression or until discontinuation criteria were met.","id":"OG000","title":"Phase 1+2: 600 mg Venetoclax + LDAC"}],"paramType":"MEDIAN","populationDescription":"Enrolled participants who received venetoclax with LDAC at the recommended Phase 2 dose (600 mg) with a response of CR or CRh","reportingStatus":"POSTED","timeFrame":"Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.","title":"Time to Best Response of CR Plus CRh","type":"SECONDARY","unitOfMeasure":"months"}